Service de Cytogénétique et Biologie Cellulaire, CHU de Rennes, 35000 Rennes, France; Université de Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en santé, environnement et travail) - UMR_S1085, 35000 Rennes, France
Auto-generated profile, based on publicly available information
Marc-Antoine Belaud-Rotureau
Service de Cytogénétique et Biologie Cellulaire, CHU de Rennes, 35000 Rennes, France; Université de Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en santé, environnement et travail) - UMR_S1085, 35000 Rennes, France
E16079 Background: Clear cell renal cell carcinoma (ccRCC) are highly metastatic tumors. Anti-vascular growth epithelial factor (VEGF) therapies are currently used in first line of metastatic ccRCC but most patients develop resistance to these treatments. Cabozantinib, an inhibitor of tyrosine kinases including VEGFR, MET and AXL recently shows interesting results in second line treatment. Moreover, the HGF/MET signaling pathway implicated in angiogenesis may be responsible for resistance to anti-VEGF therapy. To better understand MET role in metastatic ccRCC and potential resistance, we assessed MET complete status in a well-characterized population of 90 patients with metastatic ccRCC treated by first line sunitinib therapy. Methods: For this purpose, we studied MET expression by immunohistochemistry (IHC), MET amplification by fluorescence in situ hybridization (FISH) on formalin-fixed paraffin-embeded (FFPE) samples and MET mutation by next generation sequencing (NGS) on frozen samples in their 90 primary tumors. MET status was then correlated to pathological criteria using Chi-squared test and clinical outcome using Kaplan Meier curves compared by log rank test. Results: 31.1% of ccRCCs had low expression of MET (absent to weak intensity by IHC) versus 68.9% with high expression (moderate to strong intensity). High expression of MET was associated with gain in FISH analyses (p = 0.0284) without amplification. No mutation was detected by NGS. High expression of MET was associated with lymph node invasion and sarcomatoid component (p = 0.004 and p = 0.029). No statistical differences were observed between the two groups of patients in terms of progression free survival and overall survival after sunitinib introduction (p = 0.72 and p = 0.93). Conclusions: This study is the first to analyze complete MET status in metastatic ccRCC treated by sunitinib. High expression of MET, although not associated with sunitinib resistance, may suggest a benefit from MET inhibitors.